Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Key US Patent On Exosomes Technology

Capricor Therapeutics Inc (NASDAQ:CAPR) announced recently that the US Patent and Trademark Department has issued them with a key patent for cardio-sphere-derived cell exosomes. The patent which is titled, ‘Exosomes and Micro-ribonuclei Acids for Tissue Regeneration,’ will be in force up to 2033.

Exosomes are tiny membrane vesicles secreted by cells that have essential bioactive molecules containing proteins, RNS, and microRNAs, which act as key messengers in regulating the cellular functions. Exosomes have a size that makes them easy to cross the cell membranes and the ability to converse in the native cellular language thus making them potential therapeutic agents.

According to Linda Marbán, Ph.D., Capricor’s president and CEO, the issuance of the patent is a significant milestone to Capricor which is planning to expand its scope of clinical programs to develop CAP-2003 that has the ability to modulate the body cell immune response, reduce inflammation, and stimulate the growth of cells in several disease models.

The CAP-2003 contains the exosomes that are isolated from the company’s main cardio-sphere-derived cells and they are being built as the next-generation therapeutic to treat various diseases including fibrosis and inflammation. The company initially intended to create CAP-2003 to tackle the hypoplastic left heart syndrome (HLHS), a heart medical condition that usually affects more than 960 newborns annually in the US and it’s linked to high mortality rates and heart failure cases.

Capricor is still waiting for regulatory clearance for CAP-2003 which will pave way for the launch of a clinical trial in 2018 for patients who suffer from HLHS. The therapeutic potential outlook of CAP-2003 in HLHS is highly supported by various preclinical studies in which the element was examined in a form of pressure-induced ventricular dysfunction that represents a disease condition present in several single ventricle congenital heart conditions including the HLHS.

The preclinical studies were conducted at the University of Maryland by Sunjay Kaushal, M.D., associate professor of surgery and director of paediatric and adult surgery. Furthermore, Capricor recently developed biological therapies for Duchenne muscular dystrophy and other chronic medical conditions.

Abbott Michael

Abbott Michael

Michael joined US Markets Daily in 2009 and is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments.